A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-04-13

AUTHORS

Riccardo Candido, Kathleen Wyne, Ester Romoli

ABSTRACT

Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities. FUNDING: Eli Lilly and Company. More... »

PAGES

927-949

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0422-4

DOI

http://dx.doi.org/10.1007/s13300-018-0422-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103253714

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29654514


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata di Trieste, Via Puccini 48/50, 34100 Trieste, Italy", 
          "id": "http://www.grid.ac/institutes/grid.460062.6", 
          "name": [
            "Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata di Trieste, Via Puccini 48/50, 34100 Trieste, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Candido", 
        "givenName": "Riccardo", 
        "id": "sg:person.01026702544.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ohio State University Wexner Medical Center, Columbus, OH 43210 USA", 
          "id": "http://www.grid.ac/institutes/grid.412332.5", 
          "name": [
            "The Ohio State University Wexner Medical Center, Columbus, OH 43210 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wyne", 
        "givenName": "Kathleen", 
        "id": "sg:person.011721111124.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721111124.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Italia SPA, via A. Gramsci 731/733, 50019 Sesto Fiorentino, Italy", 
          "id": "http://www.grid.ac/institutes/grid.488258.b", 
          "name": [
            "Eli Lilly Italia SPA, via A. Gramsci 731/733, 50019 Sesto Fiorentino, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Romoli", 
        "givenName": "Ester", 
        "id": "sg:person.01162631537.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162631537.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00417697", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039908720", 
          "https://doi.org/10.1007/bf00417697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-009-1418-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019944234", 
          "https://doi.org/10.1007/s00125-009-1418-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13098-016-0163-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019878069", 
          "https://doi.org/10.1186/s13098-016-0163-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0226-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027355192", 
          "https://doi.org/10.1007/s40265-014-0226-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041979763", 
          "https://doi.org/10.1007/s001250051402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-009-1415-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050432421", 
          "https://doi.org/10.1007/s00125-009-1415-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-009-1444-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045209813", 
          "https://doi.org/10.1007/s00125-009-1444-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04-13", 
    "datePublishedReg": "2018-04-13", 
    "description": "Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65\u00a0years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.\nFUNDING: Eli Lilly and Company.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-018-0422-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "basal-bolus therapy", 
      "insulin glargine 100 U/mL", 
      "glargine 100 U/mL", 
      "continuous subcutaneous insulin infusion", 
      "insulin lispro", 
      "insulin glargine", 
      "diabetes mellitus", 
      "glycemic control", 
      "type 2 diabetes mellitus", 
      "less nocturnal hypoglycemia", 
      "similar glycemic control", 
      "good glycemic control", 
      "rapid-acting insulin", 
      "prandial insulin lispro", 
      "subcutaneous insulin infusion", 
      "substantial evidence base", 
      "alternative insulin", 
      "prandial components", 
      "basal insulin", 
      "adult patients", 
      "severe hypoglycemia", 
      "such regimens", 
      "nocturnal hypoglycemia", 
      "insulin infusion", 
      "glargine", 
      "T2DM", 
      "insulin preparations", 
      "lispro", 
      "patients", 
      "adult population", 
      "type 1", 
      "T1DM", 
      "insulin", 
      "evidence base", 
      "therapy", 
      "human insulin", 
      "Eli Lilly", 
      "mellitus", 
      "different ethnicities", 
      "efficacy", 
      "hypoglycemia", 
      "safety", 
      "similar levels", 
      "mL", 
      "comorbidities", 
      "regimens", 
      "infusion", 
      "years", 
      "available data", 
      "mealtimes", 
      "basal", 
      "control", 
      "ethnicity", 
      "Lilly", 
      "review", 
      "agents", 
      "population", 
      "management", 
      "data", 
      "levels", 
      "study", 
      "rate", 
      "people", 
      "use", 
      "combination", 
      "preparation", 
      "availability", 
      "components", 
      "base", 
      "companies", 
      "Basal insulin glargine 100 U/mL", 
      "U/mL"
    ], 
    "name": "A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus", 
    "pagination": "927-949", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103253714"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0422-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29654514"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0422-4", 
      "https://app.dimensions.ai/details/publication/pub.1103253714"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_759.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-018-0422-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0422-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0422-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0422-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0422-4'


 

This table displays all metadata directly associated to this object as RDF triples.

182 TRIPLES      22 PREDICATES      105 URIs      90 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0422-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N244231f4a1f44029b5f43c7fbf0ed84b
4 schema:citation sg:pub.10.1007/bf00417697
5 sg:pub.10.1007/s00125-009-1415-7
6 sg:pub.10.1007/s00125-009-1418-4
7 sg:pub.10.1007/s00125-009-1444-2
8 sg:pub.10.1007/s001250051402
9 sg:pub.10.1007/s40265-014-0226-4
10 sg:pub.10.1186/s13098-016-0163-3
11 schema:datePublished 2018-04-13
12 schema:datePublishedReg 2018-04-13
13 schema:description Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities. FUNDING: Eli Lilly and Company.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N712a192fde25482288301f963665c804
18 N93f155be21ee4363b78d9480d859a8f7
19 sg:journal.1044057
20 schema:keywords Basal insulin glargine 100 U/mL
21 Eli Lilly
22 Lilly
23 T1DM
24 T2DM
25 U/mL
26 adult patients
27 adult population
28 agents
29 alternative insulin
30 availability
31 available data
32 basal
33 basal insulin
34 basal-bolus therapy
35 base
36 combination
37 comorbidities
38 companies
39 components
40 continuous subcutaneous insulin infusion
41 control
42 data
43 diabetes mellitus
44 different ethnicities
45 efficacy
46 ethnicity
47 evidence base
48 glargine
49 glargine 100 U/mL
50 glycemic control
51 good glycemic control
52 human insulin
53 hypoglycemia
54 infusion
55 insulin
56 insulin glargine
57 insulin glargine 100 U/mL
58 insulin infusion
59 insulin lispro
60 insulin preparations
61 less nocturnal hypoglycemia
62 levels
63 lispro
64 mL
65 management
66 mealtimes
67 mellitus
68 nocturnal hypoglycemia
69 patients
70 people
71 population
72 prandial components
73 prandial insulin lispro
74 preparation
75 rapid-acting insulin
76 rate
77 regimens
78 review
79 safety
80 severe hypoglycemia
81 similar glycemic control
82 similar levels
83 study
84 subcutaneous insulin infusion
85 substantial evidence base
86 such regimens
87 therapy
88 type 1
89 type 2 diabetes mellitus
90 use
91 years
92 schema:name A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
93 schema:pagination 927-949
94 schema:productId N56153ab34b984df6bd5f0b7ef8e1c2e4
95 N80bece44f1774722a8015e99443801bf
96 Nabeef5a124a84f21bb2b15ed9830a52d
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103253714
98 https://doi.org/10.1007/s13300-018-0422-4
99 schema:sdDatePublished 2021-12-01T19:41
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher Nb0c69131b6ad4f5e8e9348ac83bf769b
102 schema:url https://doi.org/10.1007/s13300-018-0422-4
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N244231f4a1f44029b5f43c7fbf0ed84b rdf:first sg:person.01026702544.26
107 rdf:rest Nf3091f7146b846679efdc968506e50d3
108 N2881ffaffad840fd87bd11c6db8f5f2b rdf:first sg:person.01162631537.26
109 rdf:rest rdf:nil
110 N56153ab34b984df6bd5f0b7ef8e1c2e4 schema:name pubmed_id
111 schema:value 29654514
112 rdf:type schema:PropertyValue
113 N712a192fde25482288301f963665c804 schema:volumeNumber 9
114 rdf:type schema:PublicationVolume
115 N80bece44f1774722a8015e99443801bf schema:name dimensions_id
116 schema:value pub.1103253714
117 rdf:type schema:PropertyValue
118 N93f155be21ee4363b78d9480d859a8f7 schema:issueNumber 3
119 rdf:type schema:PublicationIssue
120 Nabeef5a124a84f21bb2b15ed9830a52d schema:name doi
121 schema:value 10.1007/s13300-018-0422-4
122 rdf:type schema:PropertyValue
123 Nb0c69131b6ad4f5e8e9348ac83bf769b schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 Nf3091f7146b846679efdc968506e50d3 rdf:first sg:person.011721111124.89
126 rdf:rest N2881ffaffad840fd87bd11c6db8f5f2b
127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
128 schema:name Medical and Health Sciences
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
131 schema:name Clinical Sciences
132 rdf:type schema:DefinedTerm
133 sg:journal.1044057 schema:issn 1869-6953
134 1869-6961
135 schema:name Diabetes Therapy
136 schema:publisher Springer Nature
137 rdf:type schema:Periodical
138 sg:person.01026702544.26 schema:affiliation grid-institutes:grid.460062.6
139 schema:familyName Candido
140 schema:givenName Riccardo
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026702544.26
142 rdf:type schema:Person
143 sg:person.01162631537.26 schema:affiliation grid-institutes:grid.488258.b
144 schema:familyName Romoli
145 schema:givenName Ester
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162631537.26
147 rdf:type schema:Person
148 sg:person.011721111124.89 schema:affiliation grid-institutes:grid.412332.5
149 schema:familyName Wyne
150 schema:givenName Kathleen
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011721111124.89
152 rdf:type schema:Person
153 sg:pub.10.1007/bf00417697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039908720
154 https://doi.org/10.1007/bf00417697
155 rdf:type schema:CreativeWork
156 sg:pub.10.1007/s00125-009-1415-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050432421
157 https://doi.org/10.1007/s00125-009-1415-7
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s00125-009-1418-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019944234
160 https://doi.org/10.1007/s00125-009-1418-4
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s00125-009-1444-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045209813
163 https://doi.org/10.1007/s00125-009-1444-2
164 rdf:type schema:CreativeWork
165 sg:pub.10.1007/s001250051402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041979763
166 https://doi.org/10.1007/s001250051402
167 rdf:type schema:CreativeWork
168 sg:pub.10.1007/s40265-014-0226-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027355192
169 https://doi.org/10.1007/s40265-014-0226-4
170 rdf:type schema:CreativeWork
171 sg:pub.10.1186/s13098-016-0163-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019878069
172 https://doi.org/10.1186/s13098-016-0163-3
173 rdf:type schema:CreativeWork
174 grid-institutes:grid.412332.5 schema:alternateName The Ohio State University Wexner Medical Center, Columbus, OH 43210 USA
175 schema:name The Ohio State University Wexner Medical Center, Columbus, OH 43210 USA
176 rdf:type schema:Organization
177 grid-institutes:grid.460062.6 schema:alternateName Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata di Trieste, Via Puccini 48/50, 34100 Trieste, Italy
178 schema:name Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata di Trieste, Via Puccini 48/50, 34100 Trieste, Italy
179 rdf:type schema:Organization
180 grid-institutes:grid.488258.b schema:alternateName Eli Lilly Italia SPA, via A. Gramsci 731/733, 50019 Sesto Fiorentino, Italy
181 schema:name Eli Lilly Italia SPA, via A. Gramsci 731/733, 50019 Sesto Fiorentino, Italy
182 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...